Disruption of conditioned reward association by typical and atypical antipsychotics

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 1, 2010, Pages 40-47

  Danna, C L ^a   Elmer, G I ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Antipsychotic; Autoshape; Goal tracking; Haloperidol; Incentive salience; Olanzapine; Sign tracking

Indexed keywords

AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ANHEDONIA; ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; CONDITIONING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; LEARNING; LOW DRUG DOSE; MALE; MOTIVATION; NONHUMAN; PREDICTION; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; REWARD; SENSORY GATING; STIMULUS RESPONSE; TASK PERFORMANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; ASSOCIATION LEARNING; BENZODIAZEPINES; CONDITIONING, OPERANT; HALOPERIDOL; MALE; RATS; RATS, SPRAGUE-DAWLEY; REWARD;

RATTUS;

EID: 77953292784     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.04.004     Document Type: Article

References (48)

1. Awad A.G., Voruganti L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004, 18:877-893.
2. Balsam P.D., Fairhurst S., Gallistel C.R. Pavlovian contingencies and temporal information. J Exp Psychol Anim Behav Process 2006, 32:284-294.
3. Berridge K.C. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007, 191:391-431.
4. Blackburn J.R., Phillips A.G., Fibiger H.C. Dopamine and preparatory behavior: I. Eff Pimozide Behav Neurosci 1987, 101:352-360.
5. Brown P.L., Jenkins H.M. Auto-shaping of the pigeon's key-peck. J Exp Anal Behav 1968, 11:1-8.
6. Bymaster F.P., Hemrick-Luecke S.K., Perry K.W., Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996, 124:87-94.
7. Dalley J.W., Chudasama Y., Theobald D.E., Pettifer C.L., Fletcher C.M., Robbins T.W. Nucleus accumbens dopamine and discriminated approach learning: interactive effects of 6-hydroxydopamine lesions and systemic apomorphine administration. Psychopharmacology (Berl) 2002, 161:425-433.
8. Dalley J.W., Laane K., Theobald D.E., Armstrong H.C., Corlett P.R., Chudasama Y., et al. Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA receptors in the nucleus accumbens. Proc Natl Acad Sci U S A 2005, 102:6189-6194.
9. Day J.J., Roitman M.F., Wightman R.M., Carelli R.M. Associative learning mediates dynamic shifts in dopamine signaling in the nucleus accumbens. Nat Neurosci 2007, 10:1020-1028.
10. Di Ciano P., Cardinal R.N., Cowell R.A., Little S.J., Everitt B.J. Differential involvement of NMDA, AMPA/kainate, and dopamine receptors in the nucleus accumbens core in the acquisition and performance of pavlovian approach behavior. J Neurosci 2001, 21:9471-9477.
11. Dickinson A., Smith J., Mirenowicz J. Dissociation of Pavlovian and instrumental incentive learning under dopamine antagonists. Behav Neurosci 2000, 114:468-483.
12. Elmer G.I., Pieper J.O., Levy J., Rubinstein M., Low M.J., Grandy D.K., et al. Brain stimulation and morphine reward deficits in dopamine D2 receptor-deficient mice. Psychopharmacology (Berl) 2005, 182:33-44.
13. Everitt B.J., Dickinson A., Robbins T.W. The neuropsychological basis of addictive behaviour. Brain Res Brain Res Rev 2001, 36:129-138.
14. Flagel S.B., Watson S.J., Robinson T.E., Akil H. Individual differences in the propensity to approach signals vs goals promote different adaptations in the dopamine system of rats. Psychopharmacology (Berl) 2007, 191:599-607.
15. Gamzu E.R., Williams D.R. Associative factors underlying the pigeon's key pecking in auto-shaping procedures. J Exp Anal Behav 1973, 19:225-232.
16. Gard D.E., Kring A.M., Gard M.G., Horan W.P., Green M.F. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 2007, 93:253-260.
17. Germans M.K., Kring A.M. Hedonic deficit in anhedonia: support for the role of approach motivation. Personality Individ Differ 2000, 28:659-672.
18. Gold J.M., Waltz J.A., Prentice K.J., Morris S.E., Heerey E.A. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull 2008, 34:835-847.
19. Heerey E.A., Bell-Warren K.R., Gold J.M. Decision-making impairments in the context of intact reward sensitivity in schizophrenia. Biol Psychiatry 2008, 64:62-69.
20. Heinz A., Knable M.B., Coppola R., Gorey J.G., Jones D.W., Lee K.S., et al. Psychomotor slowing, negative symptoms and dopamine receptor availability-an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophr Res 1998, 31:19-26.
21. Hermann R.C., Yang D., Ettner S.L., Marcus S.C., Yoon C., Abraham M. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv 2002, 53:425-430.
22. Juckel G., Schlagenhauf F., Koslowski M., Filonov D., Wustenberg T., Villringer A., et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 2006, 187:222-228.
23. Juckel G., Schlagenhauf F., Koslowski M., Wustenberg T., Villringer A., Knutson B., et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006, 29:409-416.
24. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003, 160:13-23.
25. Kapur S., Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001, 50:873-883.
26. Kapur S., Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000, 25:161-166.
27. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
28. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
29. King D.J., Burke M., Lucas R.A. Antipsychotic drug-induced dysphoria. Br J Psychiatry 1995, 167:480-482.
30. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 1994, 380:8-13.
31. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B., et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007, 164:630-637.
32. Morimoto T., Hashimoto K., Yasumatsu H., Tanaka H., Fujimura M., Kuriyama M., et al. Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2, 3-b][1, 5] benzodiazepine maleate). Neuropsychopharmacology 2002, 26:456-467.
33. Murray G.K., Corlett P.R., Clark L., Pessiglione M., Blackwell A.D., Honey G., et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry 2008, 13(239):67-76.
34. Parkinson J.A., Olmstead M.C., Burns L.H., Robbins T.W., Everitt B.J. Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity by D-amphetamine. J Neurosci 1999, 19:2401-2411.
35. Parkinson J.A., Willoughby P.J., Robbins T.W., Everitt B.J. Disconnection of the anterior cingulate cortex and nucleus accumbens core impairs Pavlovian approach behavior: further evidence for limbic cortical-ventral striatopallidal systems. Behav Neurosci 2000, 114:42-63.
36. Parkinson J.A., Dalley J.W., Cardinal R.N., Bamford A., Fehnert B., Lachenal G., et al. Nucleus accumbens dopamine depletion impairs both acquisition and performance of appetitive Pavlovian approach behaviour: implications for mesoaccumbens dopamine function. Behav Brain Res 2002, 137:149-163.
37. Pellegrini S., Lopez Seal M.F., Papini M.R. Scaling relative incentive value: different adjustments to incentive downshift in pigeons and rats. Behav Process 2008, 79:182-188.
38. Phillips A.G., McDonald A.C., Wilkie D.M. Disruption of autoshaped responding to a single of brain-stimulation reward by neuroleptic drugs. Pharmacol Biochem Behav 1981, 14:543-548.
39. Rescorla R.A., Solomon R.L. Two-process learning theory: relationships between Pavlovian conditioning and instrumental learning. Psychol Rev 1967, 74:151-182.
40. Robbins T.W., Everitt B.J. Limbic-striatal memory systems and drug addiction. Neurobiol Learn Mem 2002, 78:625-636.
41. Roiser J.P., Stephan K.E., den Ouden H.E., Barnes T.R., Friston K.J., Joyce E.M. Do patients with schizophrenia exhibit aberrant salience?. Psychol Med 2009, 39:199-209.
42. Schlagenhauf F., Juckel G., Koslowski M., Kahnt T., Knutson B., Dembler T., et al. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) 2008, 196:673-684.
43. Schwartz B., Gamzu E. Pavlovian control of operant behavior. Handbook of operant behavior 1977, 53-97. Prentice-Hall, Englewood Cliffs, N.J. W.K. Honig, J.E.R. Staddon (Eds.).
44. Seeman P., Van Tol H.H. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994, 15:264-270.
45. Tomie A., Aguado A.S., Pohorecky L.A., Benjamin D. Individual differences in pavlovian autoshaping of lever pressing in rats predict stress-induced corticosterone release and mesolimbic levels of monoamines. Pharmacol Biochem Behav 2000, 65:509-517.
46. Tomie A., Grimes K.L., Pohorecky L.A. Behavioral characteristics and neurobiological substrates shared by Pavlovian sign-tracking and drug abuse. Brain Res Rev 2008, 58:121-135.
47. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000, 43:135-145.
48. Wise R.A. Dopamine and reward: the anhedonia hypothesis 30years on. Neurotox Res 2008, 14:169-183.